乳腺癌患者血清TK1水平与TNM分期及化疗疗效的关系  

The relationship of the serum TK1 level with TNM classification and chemotherapeutic efficacy in breast carcinoma

作　　者：陈慧暖[1] 宋红蕾[2] 张亚平[2] 毕延智[2] 

机构地区：[1]福建中医药大学附属漳州中医院检验科,福建漳洲363000 [2]苏州大学附属常州肿瘤医院肿瘤内科,江苏常州213000

出　　处：《甘肃医药》2014年第11期814-816,共3页Gansu Medical Journal

摘　　要：目的:探讨乳腺癌患者血清胸腺嘧啶核苷激酶1(TK1)水平与乳腺癌TNM分期及化疗疗效的关系。方法:收集68例乳腺癌患者,于化疗前检测患者血清TK1水平并进行TNM分期,化疗第二个周期完成后四周评定疗效。结果:不同TNM分期的乳腺癌患者,其血清TK1水平也不相同(P<0.01),两者呈正相关(r=0.64,P<0.01);疗效评定显示完全缓解(CR)1例、部分缓解(PR)39例、稳定(SD)21例和进展(PD)7例,SD患者血清TK1水平高于化疗有效(CR+PR)的患者(P<0.01),PD的患者高于SD患者(P=0.01)。结论:血清TK1水平与乳腺癌的TNM分期相关,并可作为患者化疗预后的独立预测指标。Objective：To explore the significance of serum thymidine kinase 1 （TK1）, and find out its relationship with TNM classification and prognostic significance of chemotherapeutic efficacy in breast carcinoma. Methods：Prior to chemotherapy , the serum TK1 levels and TNM classifications were detected in 68 patients with breast carcinoma. After two cycles chemotherapy, evaluated the curative effect. Results：Different TNM classifications have different serum TK1 levels （P〈0.01）,which was positive relation （r=0.64,P〈0.01）. The results showed that 1 cases of CR, 39 cases of PR, 21 cases of SD and 7 cases of PD. The levels of serum TK1 in SD were significantly higher than CP＋PR, and PD more higher than SD （P〈0.01）. Conclusion：The levels of serum TK1 have relation to TNM classification, and it is a independent prognostic factors of chemotherapy in breast carcinoma.

关 键 词：胸腺嘧啶核苷激酶1 乳腺癌 TNM 化疗 预后 

分 类 号：R737.9[医药卫生—肿瘤]